RA Capital Management L.P. Grows Stock Holdings in Tyra Biosciences, Inc. (NASDAQ:TYRA)

RA Capital Management L.P. increased its stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) by 2.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,637,290 shares of the company's stock after purchasing an additional 220,681 shares during the period. Tyra Biosciences makes up approximately 1.9% of RA Capital Management L.P.'s investment portfolio, making the stock its 14th largest holding. RA Capital Management L.P. owned about 21.02% of Tyra Biosciences worth $147,858,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Barclays PLC increased its position in shares of Tyra Biosciences by 200.5% in the 3rd quarter. Barclays PLC now owns 37,625 shares of the company's stock valued at $884,000 after buying an additional 25,106 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Tyra Biosciences during the 3rd quarter worth about $278,000. JPMorgan Chase & Co. increased its position in shares of Tyra Biosciences by 1.1% in the third quarter. JPMorgan Chase & Co. now owns 368,647 shares of the company's stock valued at $8,667,000 after acquiring an additional 3,896 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in shares of Tyra Biosciences during the 4th quarter worth approximately $149,000. Finally, Rhumbline Advisers increased its holdings in Tyra Biosciences by 4.1% during the fourth quarter. Rhumbline Advisers now owns 26,202 shares of the company's stock worth $364,000 after buying an additional 1,027 shares during the last quarter. Institutional investors own 84.14% of the company's stock.

Insider Buying and Selling

In related news, Director Nina S. Kjellson sold 5,401 shares of Tyra Biosciences stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the transaction, the director now directly owns 443,885 shares of the company's stock, valued at $6,107,857.60. The trade was a 1.20 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 15.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TYRA shares. HC Wainwright reissued a "buy" rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Monday, March 31st. Wedbush reiterated an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Finally, UBS Group started coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They set a "buy" rating and a $28.00 target price for the company. Six analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $30.83.

Tyra Biosciences Stock Performance

TYRA stock traded down $0.80 during mid-day trading on Tuesday, hitting $9.71. The company had a trading volume of 419,094 shares, compared to its average volume of 303,346. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60. The stock's fifty day moving average price is $9.77 and its two-hundred day moving average price is $13.62. The firm has a market cap of $515.24 million, a PE ratio of -6.03 and a beta of 1.17.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last released its quarterly earnings results on Thursday, March 27th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.48) by $0.05. Equities analysts anticipate that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.